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Abstract
Background: Inflammatory stimuli induce immunoresponsive gene 1 (IRG1) expression that in turn catalyzes the
production of itaconate from the tricarboxylic acid cycle. Itaconate has recently emerged as a regulator of immune
cell functions, especially in macrophages. Studies show that itaconate is required for the activation of anti-inflammatory
transcription factor Nrf2 by LPS in mouse and human macrophages, and LPS-activated IRG1-/- macrophages that lack
endogenous itaconate production exhibit augmented inflammatory responses. Moreover, dimethyl itaconate (DMI), an
itaconate derivative, inhibits IL-17-induced IκBς activation in keratinocytes and modulates IL-17-IκBς pathway-mediated
skin inflammation in an animal model of psoriasis. Currently, the effect of itaconate on regulating macrophage
functions and peripheral inflammatory immune responses is well established. However, its effect on microglia (MG) and
CNS inflammatory immune responses remains unexplored. Thus, we investigated whether itaconate possesses an
immunomodulatory effect on regulating MG activation and CNS inflammation in animal models of multiple sclerosis,
experimental autoimmune encephalomyelitis (EAE).
Methods: Chronic C57BL/6 EAE was induced followed by DMI treatment. The effect of DMI on disease severity, blood-
brain barrier (BBB) disruption, MG activation, peripheral Th1/Th17 differentiation, and the CNS infiltration of Th1/Th17
cells in EAE was determined. Primary MG was cultured to study the effect of DMI on MG activation. Relapsing-remitting
SJL/J EAE was induced to assess the therapeutic effect of DMI.
Results: Our results show DMI ameliorated disease severity in the chronic C57BL/6 EAE model. Further analysis of the
cellular and molecular mechanisms revealed that DMI mitigated BBB disruption, inhibited MMP3/MMP9 production,
suppressed microglia activation, inhibited peripheral Th1/Th17 differentiation, and repressed the CNS infiltration of Th1
and Th17 cells. Strikingly, DMI also exhibited a therapeutic effect on alleviating severity of relapse in the relapsing-
remitting SJL/J EAE model.
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Conclusions: We demonstrate that DMI suppresses neuroinflammation and ameliorates disease severity in EAE
through multiple cellular and molecular mechanisms, suggesting that DMI can be developed as a novel therapeutic
agent for the treatment of MS/EAE through its immunomodulatory and anti-inflammatory properties.
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Background
Multiple sclerosis (MS) is an autoimmune disorder char-
acterized by immune-mediated demyelination triggered by
the CNS infiltrating myelin-specific pathogenic T cells
and subsequent neuroinflammation [1–3]. Experimental
autoimmune encephalomyelitis (EAE) is a commonly used
animal model to study MS. Studies have demonstrated
that several T cell subsets, including CD4+ T cell lineages
of Th1 and Th17, CD8+ T cells, and IL-17-producting
γδT cells, contributed to the immunopathogenisis of EAE
[4–8]. In addition, antigen presenting cells, such as den-
dritic cells, macrophages, and microglia (MG), have been
shown to play a pivotal role in the induction of encephali-
togenic T cells through releasing essential inflammatory
cytokines, such as IL-12 and IL-23 for Th1 and Th17 dif-
ferentiation, respectively [9].
Itaconate is a metabolite produced by immune cells
especially macrophages upon activation. It has been
shown that inflammatory stimuli induce immunorespon-
sive gene 1 (IRG1) expression that in turn catalyzes the
production of itaconate from the tricarboxylic acid cycle.
Itaconate has recently emerged as a regulator of macro-
phage function. For instance, it has been shown that itaco-
nate is required for the activation of anti-inflammatory
transcription factor Nrf2 by LPS in mouse and human
macrophages [10]. In addition, LPS-activated IRG1-/- mac-
rophages that lack endogenous itaconate production ex-
hibit augmented inflammatory response when compared
to LPS-activated wild-type macrophages [11]. Moreover, a
recent study demonstrates that in addition to its regula-
tory effects on immune responses through activating
Nrf2/HO-1 pathway, itaconate is capable of modulating
immune responses through an Nrf2-independent mechan-
ism. The study shows that dimethyl itaconate (DMI), a
cell-permeable itaconate derivative, inhibits IL-17-induced
IκBς activation in keratinocytes, and the immunomodula-
tory effect of DMI on regulating the IL-17-IκBς axis-
induced inflammation can also be observed in the
imiquimod-induced psoriasis animal model [12].
MG make up the innate immune system of the CNS
and are the key cellular mediators of neuroinflammatory
processes [13–15]. MG activation leads to increased
secretion of inflammatory cytokines and enhanced ex-
pression of surface maturation markers. In MS, homeo-
static MG were completely lost in active and slowly
expanding lesions. In contrast, activated MG with
elevated expression of pro-inflammatory genes were
highly observed around lesions in the brain of MS pa-
tients [16], suggesting that MG activation is linked to
the disease development of MS.
Currently, the effect of itaconate on regulating macro-
phage functions and peripheral inflammatory immune re-
sponses is well established. However, its effect on MG and
CNS inflammatory immune responses remains unexplored.
In the present study, we investigated whether itaconate pos-
sesses an immunomodulatory effect on regulating MG acti-
vation and CNS inflammation in EAE. We reported for the
first time that DMI, a derivative of itaconate, not only ame-
liorated disease severity in chronic EAE but also mitigated
disease relapse in relapsing-remitting EAE. In addition, we
identified that DMI suppressed MG activation, attenuated
neuroinflammation, lessened BBB disruption, inhibited per-
ipheral Th1/Th17 differentiation, and repressed the CNS
infiltration of Th1/Th17 in EAE.
Methods and materials
Animals
C57BL/6 and SJL/J mice used in this study were pur-
chased from The Jackson Laboratory (Bar Harbor, ME).
Mice were housed in animal housing rooms with con-
trolled temperature, humidity, and 12 h∶12 h light∶-
dark cycle and bred with free accessed food and water.
All animal-associated studies were approved by the Pur-
due University Animal Care and Use Committee.
Reagents
Dimethyl itaconate (DMI), Complete Freund’s adjuvant,
Evans blue, trichloroacetic acid (TCA), phorbol myristate
acetate (PMA), ionomycin, and paraformaldehyde were
purchased from Sigma-Aldrich (St. Louis, MO). Antibodies
of Alexa Fluor 488 anti-mouse CD4 (clone: RM4-5), APC
anti-mouse IL-17A (clone: TC11-18H10.1), PE/Cy7 anti-
mouse IFNγ (clone: XMG1.2), APC anti-mouse CD45
(clone: 30-F11), PE anti-mouse CD11b (clone: M1/70), PE/
Cy7 anti-mouse CD80 (clone: 16-10A1), PE/Cy7 anti-
mouse CD86 (clone: GL-1), PE anti-mouse CD25 (clone:
PC61), Alexa Fluor 647 anti-mouse Foxp3 (clone: MF-14),
anti-mouse CD68 (clone: FA-11), anti-mouse MMP9
(clone: L51/82), anti-mouse MMP3 (clone: M4405F10),
anti-mouse CD3 (clone: 145-211), anti-mouse CD28 (clone:
37.51) and anti-mouse IFNγ (clone: R4-6A2), reagents of
brefeldin A solution, fixation buffer and permeabilization
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wash buffer, and recombinant cytokines of mouse IL-12,
mouse IL-6, and human TGFβ were purchased from BioLe-
gend (San Diego, CA). Anti-IBA1 antibody was purchased
from Fujifilm Wako Chemicals (Richmond, VA). Alexa
Fluor 488- and Alexa Fluor 647-conjugated secondary
antibodies and ProLong Gold antifade mountant con-
taining DAPI were purchased from Invitrogen,
Thermo Fisher Scientific (Waltham, MA, USA). Anti-
bodies of anti-mouse Nrf2, anti-mouse HO-1, and
anti-mouse GAPDH were purchased from Proteintech
(Rosemont, IL). Mycobacterium tuberculosis H37 RA and
anti-mouse β-actin antibody were purchased from BD
Biosciences (San Jose, CA). Pertussis toxin was purchased
from List Biological Labs (Campbell, CA). Percoll was pur-
chased from GE Healthcare Life Sciences (Pittsburgh, PA).
EAE induction
For chronic EAE induction, female C57BL/6 mice with
an age of 8–9 weeks old were injected subcutaneously
with an emulsion of 200 μg MOG35–55 peptide in
Complete Freund’s adjuvant containing Mycobacterium
tuberculosis H37 RA (final concentration 2mg/ml) on
day 0 followed by intraperitoneal administration with
200 ng pertussis toxin on day 0 and day 2. For relapsing-
remitting EAE induction, female SJL/J mice with an age
of 8–9 weeks old were injected subcutaneously with
100 μg PLP139–151 peptide in Complete Freund’s adju-
vant containing Mycobacterium tuberculosis H37 RA
(final concentration 2 mg/ml) on day 0 followed by in-
traperitoneal administration with 200 ng pertussis toxin
on day 0 and day 2. The immunized mice were ran-
domly grouped and administered intraperitoneally (i.p.)
with vehicle (DMSO) or DMI every day, starting from
day 3 post-immunization (C57BL/6 model) or starting
from the first remission when animals reached the dis-
ease score of ≤ 1.5 (SJL/J model). C57BL/6 and SJL/J
EAE mice were subjected to clinical score evaluation
everyday based on the following criteria: 0: normal
mouse and no overt signs of disease, 1: limp tail or hind
limb weakness, 2: limp tail and hind limb weakness, 3:
partial hind limb paralysis, 4: complete hind limb paraly-
sis, 5: moribund state. Animals with clinical scores of 5
were euthanized.
Evans blue BBB permeability assay
The Evans blue permeability assay was conducted as
previously described [17]. EAE mice were administered
intravenously (i.v.) with 4ml/kg 2% (w/v) Evans blue
dye/0.9% saline solution from lateral tail vein at day 12
post-immunization. Two hours after Evans blue injec-
tion, mice were anesthetized and perfused with PBS
buffer. The brain and spinal cord were harvested and
subjected to imaging to observe Evans blue leakage. The
spinal cord tissues were then weighted and homogenized
in 50% TCA solution followed by incubation at 4 °C for
overnight. Following centrifugation, the supernatants
were collected and diluted with 95% ethanol in the ratio
of 1:3. The amount of Evans blue in the spinal cord
tissues was determined by measuring the fluorescence
with excitation at 540/25 nm and emission at 645/40 nm
(BioTek Synergy HT microplate reader).
Cell cultures
Primary MG were obtained following procedures de-
scribed previously [18]. Briefly, cerebral cortical cells
were collected from 1 to 2 days old neonatal mice and
seeded in T75 flasks containing Dulbecco Modified
Eagle Medium/F12 (HyClone™) with 2 mM glutamine,
1× antibiotic/antimycotic, and 10% heat-inactivated FBS
(complete medium). After removing medium, cells were
replenished with fresh complete medium containing 10
ng/ml GM-CSF on day 3 and 6 after plating. MG were
collected by shaking the flasks at 250 rpm for 30 min at
37 °C on day 13 or 14. After seeding, MG were treated
according to the conditions described. BV2 mouse brain
microglial cell lines obtained from American Type
Culture Collection were grown to confluence. After tryp-
sinization, cells were then seeded onto tissue culture
plates followed by stimulation as described.
Western blot analysis
Cells or tissue samples were lysed in radioimmunopreci-
pitation assay buffer [50 mM Tris-HCl (pH 8.0), 150 mM
NaCl, 1% NP-40, 0.5% sodium deoxycholate] plus 1X
protease inhibitor cocktail III (Alfa aesar) with 0.1% SDS
(cells) or 0.3% SDS (tissues). Protein concentrations were
measured by using Pierce™ BCA Protein Assay Kit
(Thermo Fisher Scientific). Ten micrograms (cells) or
50 μg (tissues) of whole protein lysate was mixed with
sample buffer, boiled for 10 min, and loaded on 10%
SDS-PAGE gels followed by electrophoresis. Separated
proteins were transferred to polyvinylidene difluoride
membranes (Millipore) and then probed with antibodies
against MMP9, MMP3, GAPDH, Nrf2, HO-1, or β-actin
in blocking buffer. HRP-conjugated goat anti-rabbit IgG
or anti-mouse IgG antibodies (BD Biosciences) were
used as secondary antibodies. The membranes were then
incubated with Immobilon™ Western Chemiluminescent
HRP Substrate (Millipore) followed by the detection of
protein signals by using X-ray films. The quantification
of protein signal was measured by using ImageJ.
Immunohistochemistry
Paraffin-embedded lumbar regions of spinal cord sam-
ples were cut into 8 μm sections by the microtome
(Leica RM2155). The slides were deparaffinized followed
by antigen retrieval with 10 mM citrate buffer for 20 min
at 90 °C. The slides were then incubated with anti-IBA1
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antibody (1:500) at 4 °C overnight. After incubation, the
sections were rinsed with PBS and incubated with Alexa
488-conjugated secondary antibody (1:1000) for 1 h at
room temperature (RT). After washing with PBS, sam-
ples were coverslipped with ProLong Gold antifade
mountant containing DAPI. Two sections from each
spinal cord sample were stained. Immunofluorescence
images were captured with fluorescence microscope
(BX53, Olympus; camera: EXi Aqua, Q Imaging), and
the number of IBA1+ cells per mm2 was then counted
and quantified by imageJ.
Immunocytochemistry
MG were fixed with 2% paraformaldehyde for 15 min at
RT and then permeabilized with 0.25% Triton X-100 for
10 min. After blocking with 5% normal donkey serum
for 30 min at RT, MG were incubated with anti-mouse
CD68 (1:500) or anti-mouse HO-1 (1:50) for 2 h at RT.
MG were then rinsed with PBS and incubated with
Alexa Fluor 488- or Alexa Fluor 647-conjugated second-
ary antibody (1:1000) for 1 h. After washing with PBS,
samples were coverslipped with ProLong Gold antifade
mountant containing DAPI. Immunofluorescence im-
ages were then captured with the Fluoview FV10i con-
focal microscope (Olympus).
Real-time quantitative PCR (Q-PCR)
Primary MG were subjected to RNA extraction followed by
cDNA synthesis. The mRNA expression of Il-1α, Il-1β, Il-
12p35, Il-12p40, Il-23p19, and Gm-csf was measured by Q-
PCR. The primers used were Il-1α: sense 5′-CGCTTG
AGTCGGCAAAGAAAT-3′ and antisense 5′-CTTCCC
GTTGCTTGACGTTG-3′; Il-1β: sense 5′-CCCTGCAGCT
GGAGAGTGTGGA-3′ and antisense 5′-TGTGCTCTGC
TTGGAGGTGCTG-3′; Il-12p35: sense 5′-CTGTGC
CTTGGTAGCATCTATG-3′ and anti-sense 5′-GCAGAG
TCTCGCCATTATGATTC-3′; Il-12p40: sense 5′-
TGGTTTGCCATCGTTTTGCTG-3′ and antisense 5′-
ACAGGTGAGGTTCACTGTTTCT-3′; Il-23p19: sense
5′-TGCTGGATTGCAGAGCAGTAA-3′ and anti-sense
5′-GCATGCAGAG ATTCCGAGAGA-3′; Gm-csf: sense
5′-ATGCCTGTCACGTTGAATGAAG-3′ and anti-sense
5′-GCGG GTCTGCACACATGTTA-3′.
Isolation of mononuclear cells from brain and spinal cord
tissues
Mononuclear cell isolation was processed as previously
described [19]. Briefly, at day 12–14 post-immunization,
vehicle- and DMI-treated EAE mice were anesthetized,
and the brain and spinal cord were then harvested and
homogenized with 1× HBSS buffer followed by filtration
through 70 μm nylon cell strainers. After centrifugation,
cells were resuspended in 30% Percoll and underlayered
with 70% Percoll. The samples were then centrifuged at
RT for 25 min at 1000 g, and the mononuclear cells were
isolated from the interface between 30% and 70% Percoll
followed by FACS analysis.
In vitro Th1 and Th17 differentiation
Splenocytes (2 × 106 cells/well) isolated from the spleen
of C57BL/6 mice were activated with plate-coat anti-
mouse CD3 antibody (3 μg/ml) and soluble ant-mouse
CD28 antibody (2 μg/ml) in the presence of IL-12 (10
ng/ml) for Th1 differentiation or IL-6 (20 ng/ml), TGFβ
(10 ng/ml), and anti-mouse IFNγ antibody (5 μg/ml) for
Th17 differentiation. Forty-eight hours later, cells were
then collected and subjected to FACS analysis for intra-
cellular expression of IFNγ and IL-17 in CD4+ cells.
FACS analysis for surface markers, intracellular cytokines
and Foxp3 expression
For MG surface marker analysis, isolated mononuclear
cells were stained with PE anti-mouse CD11b and APC
anti-mouse CD45 in the combination with PE/Cy7 anti-
mouse CD80 or PE/Cy7 anti-mouse CD86 followed by
FACS analysis. For intracellular cytokine analysis, cells
isolated from spleens and cervical lymph nodes or
mononuclear cells isolated from the spinal cord and
brain of C57BL/6 EAE animals were stimulated with
PMA (50 ng/ml), ionomycin (750 ng/ml), and brefeldin
A solution (1 μl/ml). After 5 h of stimulation, cells were
then fixed and permeabilized followed by staining with
antibodies of Alexa Fluor 488 anti-mouse CD4, PE/Cy7
anti-mouse IFNγ, and APC anti-mouse IL-17. The intra-
cellular expression of IFNγ and IL-17 in CD4+ cells was
then determined by FACS analysis. For Foxp3 expres-
sion, isolated cells were stained with Alexa Fluor 488
anti-mouse CD4 and PE anti-mouse CD25. Following
fixation and permeabilization, cells were then stained
with Alexa Flour 647 anti-mouse Foxp3 followed by
FACS analysis to determine Foxp3 expression in
CD4+CD25+ cells.
Statistical analysis
Experimental results were given as mean ± SEM. For
each measured variable, the Shapiro-Wilk normality test
was performed to assess whether values were normally
distributed. For normally distributed variables, compari-
sons between two groups were done by using the un-
paired t test, whereas comparisons between multiple
groups were done by one-way ANOVA followed by
Bonferroni post hoc test. For variables displaying a non-
Gaussian distribution, comparisons between two groups
were done by using the Mann-Whitney U test. Statistical
significance was determined as p values ≤ 0.05. All statis-
tical analysis was performed by using the GraphPad
Prism 8 software (La Jolla, CA).
Kuo et al. Journal of Neuroinflammation          (2020) 17:138 Page 4 of 15
Results
DMI ameliorates disease severity in chronic EAE
To investigate the potential therapeutic effect of DMI in
EAE, C57BL/6 mice were immunized with MOG35–55
followed by vehicle or DMI administration every day
starting from day 3 post-immunization. The clinical
score of vehicle- and DMI-treated EAE mice was
assessed for a period of 30 days. Our results show that
although DMI 300mg/kg treatment did not offer a pro-
tection against EAE (Fig. S1A), DMI 400 mg/kg treat-
ment exerted a protective effect and ameliorated disease
severity in EAE (Fig. 1a). The maximum disease score in
DMI-treated EAE mice was lower compared to that in
vehicle-treated EAE mice (vehicle 4.2 ± 0.1 vs. DMI
3.5 ± 0.2; Fig. 1b). Further comparison of cumulative dis-
ease score between vehicle- and DMI-treated EAE mice
revealed that DMI-treated EAE mice had a significant
lower cumulative disease score than vehicle-treated
EAE controls (vehicle 58.9 ± 2.4 vs. DMI 40.2 ± 3.3;
Fig. 1b). Furthermore, EAE mice were treated with
DMI 500 mg/kg or 600 mg/kg to assess whether in-
creased doses of DMI would offer a better protection
against EAE. The outcomes of disease onset and max-
imum disease score in EAE were comparable among
DMI treatment doses of 400, 500, and 600 mg/kg
(Fig. 1b and Fig. S1B). Although DMI treatment of
500 mg/kg and 600 mg/kg slightly reduced cumulative
disease score compared to DMI treatment of 400 mg/
kg in EAE, the differences did not reach statistical
significance (data not shown). Thus, the DMI dose of
400 mg/kg was selected to continue with the studies.
Taken altogether, these results demonstrate that DMI
confers protection against EAE through ameliorating
disease severity in EAE.
DMI alleviates BBB disruption in EAE
BBB disruption followed by inflammatory immune cell
infiltration is a hallmark of immune-mediated inflamma-
tion of the CNS in MS and EAE [20, 21]. To elucidate
whether DMI treatment alleviates BBB disruption in
EAE, mice immunized with MOG35–55 and treated with
vehicle or DMI were subject to Evans blue administra-
tion, and the CNS tissues were then harvested to assess
BBB integrity. Our results show that there was an
increased Evans blue leakage in the spinal cord of
vehicle-treated EAE mice, suggesting BBB integrity was
compromised. In contrast, Evans blue leakage was not
clearly observed in the spinal cord of DMI-treated EAE
mice (Fig. 2a). We then quantified the amount of Evans
blue leakage in the spinal cord tissue of vehicle- and
DMI-treated EAE mice, and our results show there was
a significant reduction of Evans blue leakage in the
spinal cord of DMI-treated EAE mice compared to that
in vehicle-treated EAE mice (Fig. 2b). In addition, we ob-
served that DMI-mediated mitigation of BBB disruption
was highly correlated with DMI-mediated alleviation of
disease severity in EAE mice (Fig. 2c).
Induction of MMP3 and MMP9 expression leads to
BBB disruption in neuroinflammatory diseases, including
MS/EAE [22–24]. To elucidate whether BBB disruption
in the spinal cord of EAE mice is due to increased pro-
duction of MMP3 and MMP9, the spinal cord tissues
Fig. 1 DMI ameliorates disease severity in chronic EAE. C57BL/6 mice were immunized with MOG35–55 and administered i.p. with vehicle (n = 15)
or 400 mg/kg DMI (n = 20) every day starting from day 3 post-immunization. a The clinical score of EAE animals was followed for a period of 30
days. b The incidence and mortality rate of vehicle- and DMI-treated EAE mice were accessed, and the mean ± SEM of onset of disease,
maximum score, and cumulative score (day 1 to day 30 post-immunization) in vehicle- and DMI-treated EAE was also calculated. Statistical
significance was determined as *p < 0.05, **p < 0.01, and ***p < 0.001 by Mann-Whitney U test
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harvested from vehicle- and DMI-treated EAE mice were
lysed and subjected to western blots analysis to deter-
mine MMP3 and MMP9 expression. We observed
MMP3 and MMP9 were highly expressed in the spinal
cord of vehicle-treated EAE mice. Conversely, MMP3
and MMP9 were strongly inhibited in the spinal cord of
DMI-treated EAE mice (Fig. 2d). Altogether, these results
suggest that DMI-mediated suppression of MMP3 and
MMP9 production may contribute to the alleviation of BBB
disruption in the spinal cord of DMI-treated EAE mice.
DMI suppresses MG activation in EAE
To investigate whether DMI exerts a modulatory effect
on MG activation, the brain and spinal cord were
harvested from vehicle- and DMI-treated EAE mice
followed by mononuclear cell isolation. The isolated
cells were subjected to FACS analysis to determine MG
maturation status based on their expression of CD80
and CD86. Although there was no significant difference
in the number of CD86+ MG, CD80+ MG were largely
reduced in the brain and spinal cord of DMI-treated
EAE mice compared to that in vehicle-treated EAE con-
trols (Fig. 3a). In addition, IBA1+ MG/macrophages were
also determined in the spinal cord, and our results show
that the number of IBA1+ cells was significantly lower in
the lumbar regions of spinal cord of DMI-treated EAE
mice compared to that in vehicle-treated EAE controls.
(Fig. 3b). Altogether, these results demonstrate that DMI
suppresses MG activation in EAE.
DMI inhibits MG activation and inflammatory cytokine
production and enhances Nrf2/HO-1 defense pathway in
MG
To further confirm the inhibitory effect of DMI on MG
activation, primary MG were cultured and activated with
LPS in the presence or absence of DMI. MG were then
subjected to immunofluorescence staining and Q-PCR
analysis to determine the activation marker CD68 expres-
sion and inflammatory cytokine production, respectively.
LPS strongly induced CD68 expression in primary MG.
However, LPS-induced CD68 expression was abolished in
the presence of DMI (Fig. 4a). Furthermore, GM-CSF,
which has been shown to promote neuroinflammation
and mediate immunopathology in EAE [25, 26], was
highly upregulated by LPS in MG. However, LPS-induced
GM-CSF upregulation was abolished by DMI in MG.
Moreover, inflammatory cytokines IL-23p19 required for
Th17 differentiation and IL-12p35 and IL-12p40 required
for Th1 differentiation were upregulated in LPS-treated
MG, but were strongly suppressed in LPS +DMI-treated
MG. DMI also suppressed LPS-induced IL-1α and IL-1β
expression in MG (Fig. 4b).
Induction of Nrf2/HO-1 pathway has been shown
to promote anti-oxidant and anti-inflammatory effects
[27, 28]. It has been shown that DMI induced Nrf2
activation in macrophages [10]. Here, we investigated
whether DMI induces Nrf2/HO-1 pathway in MG.
Microglial cell lines, BV2 cells, were treated with LPS
in the presence or absence of DMI for a time course.
Our results show that DMI enhanced Nrf2 expression
at early time points and upregulated HO-1 expression
at late time points in BV2 cells (Fig. 4c). DMI-
mediated HO-1 upregulation was further confirmed in
primary MG by immunofluorescence staining, and
our results show that HO-1 expression was strongly
induced by DMI in LPS-treated MG (Fig. 4d).
DMI represses the CNS infiltration of encephalitogenic
Th1 and Th17 cells in EAE
Given that the CNS infiltration of encephalitogenic Th1
and Th17 cells plays a pivotal role in the pathogenesis of
EAE, we tested whether DMI suppresses pathogenic
CD4+ T cell infiltration of the CNS. Mononuclear cells
were isolated from the brain and spinal cord of vehicle-
and DMI-treated EAE mice, and the isolated cells were
then subjected to FACS analysis to determine the num-
ber of the CNS infiltrating CD4+ T cells as well as IFNγ-
and IL-17-expressing CD4+ T cells. Significant CD4+ T
cell infiltrates were observed in the brain and spinal cord
of vehicle-treated EAE mice. In contrast, CD4+ T cell in-
filtrates were suppressed in the brain and spinal cord of
DMI-treated EAE mice (Fig. 5a). Further analysis of Th1
and Th17 infiltration of the CNS revealed that both Th1
and Th17 infiltrates were decreased in the brain and
spinal cord of DMI-treated EAE mice compared to those
in vehicle-treated EAE controls (Fig. 5b, c). In addition,
the frequency of T regulatory cells (Tregs) in the CNS of
vehicle- and DMI-treated EAE mice was evaluated. Our
results show that the frequency of Foxp3-expressing
CD4+CD25+ cells in the brain and spinal cord of DMI-
treated EAE mice was comparable to that in vehicle-
treated EAE controls (Fig. S2), suggesting that DMI did
not alter the frequency of Tregs in the CNS of EAE.
Altogether, these results demonstrate that DMI re-
presses encephalitogenic Th1 and Th17 cell infiltration
of the CNS that may contribute to ameliorated disease
severity in DMI-treated EAE mice.
DMI suppresses Th1 and Th17 differentiation in vivo and
in vitro
To elucidate whether DMI modulates peripheral Th1
and Th17 differentiation in EAE, cells were isolated from
the spleen and cervical lymph nodes (CLNs) of vehicle-
and DMI-treated EAE mice at day 10 post-immunization
followed by FACS analysis for the intracellular expression
of IFNγ and IL-17 in CD4+ cells. Although a similar fre-
quency of IFNγ- and IL-17-expressing CD4+ T cells was
observed in the CLNs of vehicle- and DMI-treated EAE
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Fig. 2 DMI alleviates BBB disruption. C57BL/6 EAE animals were administered i.p. with vehicle or DMI (400 mg/kg) every day starting from day 3
post-immunization. At day 12 post-immunization, vehicle- and DMI-treated EAE mice (n = 9/group) were subjected to i.v. administration of Evans
blue. a EAE mice were sacrificed at 2 h post-Evans blue administration. The brain and spinal cord of vehicle- and DMI-treated EAE mice were
harvested to assess the leakage of Evans blue. The four representative images of the brain and spinal cord harvested from vehicle- and DMI-
treated EAE mice are shown. b The amount of Evans blue in the spinal cord tissues was measured and quantified. Statistical significance was
determined as ***p < 0.001 by unpaired t test. c The correlation between Evans blue leakage and disease score was determined by linear
regression analysis. d The spinal cord tissues harvested from vehicle- and DMI-treated EAE mice (n = 5/group) were homogenized and subjected
to western blot analysis of MMP3 and MMP9 expression followed by quantification. Statistical significance was determined as *p < 0.05
and **p < 0.01 by Mann-Whitney U test
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mice (Fig. S3A), the frequency of IFNγ- and IL-17-
expressing CD4+ T cells was decreased in the spleen of
DMI-treated EAE mice compared to that in vehicle-
treated EAE controls (Fig. 6a). In addition, to evaluate
whether DMI treatment affects Treg differentiation in the
periphery of EAE mice, cells isolated from the spleen and
CLNs of vehicle- and DMI-treated EAE mice were sub-
jected to FACS analysis to determine the frequency of
Tregs. Our results show that DMI treatment did not alter
the frequency of Foxp3-expressing CD4+CD25+ cells in
the spleen and CLNs compared to vehicle treatment in
EAE (Fig. 6b and Fig. S3B). Finally, to determine whether
DMI exerts a direct suppressive effect on the differenti-
ation of pathogenic T cells, naive splenocytes were polar-
ized into Th1 or Th17 cells in the presence or absence of
DMI followed by FACS analysis for the intracellular
Fig. 3 DMI suppresses MG activation in EAE. a C57BL/6 mice (n = 8/group) subjected to EAE were administered with vehicle or DMI (400 mg/kg)
every day starting from day 3 post-immunization. At day 12–14 post-immunization, mononuclear cells were isolated from the brain and spinal
cord of vehicle- and DMI-treated EAE mice. The isolated cells were then subjected to staining of CD45 and CD11b with CD80 or CD86 followed
by FACS analysis. MG were determined based on their expression of CD45intCD11b+, and the surface expression of CD80 and CD86 on
CD45intCD11b+ cells was then determined. Isotype controls (ISO) were used as a negative control to determine MG positive for CD80 or CD86
expression. b At day 12 post-immunization, the lumbar region of spinal cord tissues harvested from vehicle- and DMI-treated EAE mice (n = 5/
group) was subjected to immunofluorescence analysis of IBA1 expression. The number of IBA1+ cells was calculated and quantified. Scale bars,
top 200 μm and bottom 100 μm. Statistical significance was determined as ***p < 0.001 and N.S., no significant difference by unpaired t test
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expression of IFNγ and IL-17 in CD4+ T cells. We ob-
served that DMI suppressed the frequency of IFNγ-
and IL-17-expressing CD4+ cells in the polarized Th1
and Th17 splenocyte cultures, respectively, suggesting
that DMI possesses a direct inhibitory effect on Th1
and Th17 differentiation (Fig. 6c). Taken altogether,
our results demonstrate that DMI suppresses the dif-
ferentiation of pathogenic Th1 and Th17 cells in the
periphery that may contribute to the decreased infil-
tration of encephalitogenic Th1 and Th17 cells in the
CNS of DMI-treated EAE mice.
DMI alleviates the severity of relapse in relapsing-
remitting EAE
To further explore whether DMI possesses a therapeutic
effect on alleviating the severity of relapse in EAE,
relapsing-remitting EAE was induced in SJL/J mice, and
EAE mice were administered with vehicle or DMI start-
ing from the first remission before the onset of relapse.
EAE mice treated with vehicle developed disease relapse
following remission with the maximum disease score
and cumulative disease score of post-treatment reaching
4.0 ± 0.2 and 52.2 ± 3.5, respectively. In contrast, EAE
Fig. 4 DMI inhibits MG activation and inflammatory cytokine production and enhances Nrf2/HO-1 defense pathway in MG. Primary MG or BV2
cells were left untreated (MED) or pretreated with vehicle or DMI 150 μM for 1 h followed by LPS (100 ng/ml) stimulation. a 24 h after LPS
stimulation, primary MG were subjected to CD68 staining to assess MG activation. The representative confocal images of three independent
experiments are shown. Scale bar, 20 μm. b 1.5 h after LPS stimulation, primary MG were collected and subjected to RNA extraction followed by
Q-PCR analysis for mRNA expression of GM-CSF, IL-23p19, IL-12p35, IL-12p40, IL-1α, and IL-1β. The representative results of three independent
experiments are shown. Statistical significance was determined as **p < 0.01 and ***p < 0.001 by one-way ANOVA with post-hoc Bonferroni’s
multiple comparison test. c 1.5, 3, and 5 h after LPS stimulation, BV2 cells were collected and subjected to western blot analysis for Nrf2 and HO-1
expression. The representative results of three independent experiments are shown. d 8 h after LPS stimulation, primary MG were subjected to
immunofluorescence analysis to determine HO-1 expression. The representative confocal images of four independent experiments are shown.
Scale bar, 20 μm
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mice treated with DMI displayed alleviated severity of
relapse with the maximum disease score and cumulative
disease score of post-treatment only reaching 2.6 ± 0.4
and 29.5 ± 4.7, respectively (Fig. 7). Collectively, these re-
sults demonstrate that DMI possesses a therapeutic ef-
fect on alleviating the severity of relapse in EAE, and
suggest that DMI can be developed as a novel therapy
for the treatment of MS/EAE.
Discussion
Itaconate, a metabolite synthesized by the enzyme
encoded by IRG1, has recently emerged as a regulator of
macrophage functions [10–12, 29]. It has been shown
that itaconate exerts an anti-inflammatory effect through
suppressing succinate dehydrogenase (SDH) activity, a
crucial pro-inflammatory regulator [30]. In addition, ita-
conate was reported to activate Nrf2/HO-1 pathway
which possesses anti-oxidant and anti-inflammatory
effects [10, 31]. Moreover, itaconate has been shown
to inhibit LPS-induced IκBς activation in macrophages
and IL-17-induced IκBς activation in keratinocytes,
leading to suppression of IL-6 and IL-12 production and
amelioration of psoriatic pathology, respectively [12]. Pres-
ently, the anti-inflammatory effect of itaconate was mostly
reported in macrophages and peripheral inflammatory im-
mune responses, and little is known with regard to its ef-
fect on MG and the CNS inflammation. Thus, in this
study, we aimed to explore the effect of itaconate on MG
Fig. 5 DMI represses the CNS infiltration of encephalitogenic Th1 and Th17 cells in EAE. C57BL/6 mice (n = 8/group) were subjected to EAE
induction followed by i.p. administration with vehicle or DMI (400 mg/kg) every day starting from day 3 post-immunization. At day 12–14 post-
immunization, mononuclear cells were isolated from the brain and spinal cord of vehicle- and DMI-treated EAE mice. The number of (a) CD4+ T
cells, (b) IFNγ-expressing CD4+ T cells, and (c) IL-17-expressing CD4+ T cells in the brain and spinal cord of vehicle- and DMI-treated EAE mice was
determined by FACS analysis. ISO were used as a negative control to determine cells positive for the surface expression of CD4 or CD4+ cells positive
for the intracellular expression of IFNγ or IL-17. Statistical significance was determined as *p < 0.05, **p < 0.01, and ***p < 0.001 by unpaired t test
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and neuroinflammation using EAE models. Similar to its
immunomodulatory effect on macrophages, DMI sup-
pressed MG activation, and this immunomodulatory effect
of DMI on MG was observed both in vitro and in vivo. In
vitro, DMI inhibited LPS-induced inflammatory cytokine
production in MG and suppressed LPS-induced MG acti-
vation. In vivo, DMI suppressed MG activation in EAE in
which the number of CD80+ MG and IBA1+ MG/macro-
phages in the CNS of DMI-treated EAE mice was signifi-
cantly lower than that in vehicle-treated EAE controls.
Thus, our findings demonstrate the immunomodulatory
effect of DMI on LPS-induced MG activation and MG-
mediated neuroinflammation in EAE.
Although the molecular mechanisms by which DMI
suppresses MG activation and neuroinflammation in
EAE were not investigated in this study, we speculated
that the protective effect of DMI in EAE may be medi-
ated through two major mechanisms, namely activation
of Nrf2/HO-1 pathway and suppression of SDH/HIF-1α
activity. The induction of Nrf2/HO-1 pathway has been
shown to confer a protection against EAE [19, 32–34].
Similar to the previous findings of DMI induced Nrf2
activation in macrophages [10, 12], we observed DMI
enhanced Nrf2 and HO-1 expression in MG. Further-
more, itaconate has been shown to inhibit SDH activity
that leads to the repression of succinate accumulation
Fig. 6 DMI suppresses Th1 and Th17 differentiation in vivo and in vitro. Cells were harvested from the spleen of vehicle- and DMI (400 mg/kg)-
treated EAE mice (n = 7/group) at day 10 post-immunization. a IFNγ- and IL-17-expressing CD4+ cells and b Foxp3-expressing CD4+CD25+ cells
were determined by FACS analysis. ISO were used as a negative control to determine CD4+ cells positive for the intracellular expression of IFNγ
or IL-17 or CD4+CD25+ cells positive for the nuclear expression of Foxp3. Statistical significance was determined as *p < 0.05. N.S., no significant
difference by unpaired t test. c Naive splenocytes were harvested and polarized into Th1 or Th17 condition in the absence or presence of DMI
(150 μM). Forty-eight hours later, cells were harvested and subjected to FACS analysis for the intracellular expression of IFNγ or IL-17 in
CD4+ T cells. ISO were used as a negative control to determine CD4+ cells positive for the intracellular expression of IFNγ or IL-17. The
representative data of three independent experiments are shown
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and subsequent HIF-1α activation as well as IL-1β produc-
tion [29, 30, 35, 36]. As HIF-1α activation was reported to
promote Th17 differentiation [37, 38], itaconate-mediated
repression of HIF-1α activation may result in hindering
Th17 differentiation. Taken altogether, it suggests that Nf2/
HO-1 pathway activation and SDH/HIF-1α activity sup-
pression may account for the two major molecular mecha-
nisms underlying the protective effect of DMI in EAE,
although it would require further studies to demonstrate
the proposed mechanisms.
The BBB is a complex organization composed of cere-
bral endothelial cells, pericytes, and basal lamina, sur-
rounded by astrocytes and perivascular macrophages [39].
These cells separate and form the compartments of the
cerebral vascular space during homeostasis. The BBB dys-
regulation and the CNS transendothelial migration of acti-
vated immune cells are associated with cerebrovascular
abnormalities observed in MS/EAE. Similar to the previ-
ous findings [40, 41], we observed profound extravasation
of Evans blue in the spinal cord of EAE mice. However,
Evans blue extravasation was significantly reduced in the
spinal cord of DMI-treated EAE mice, suggesting that
DMI possesses a protective effect on the alleviation of
BBB disruption in EAE. Notably, DMI-mediated allevi-
ation of BBB disruption is correlated with reduced Th1
and Th17 infiltration into the spinal cord of DMI-treated
EAE mice. Studies have shown that MMP3 and MMP9
play a detrimental role in BBB disruption [20, 21]. Con-
sistently, our results show that MMP3 and MMP9 were
highly upregulated in the spinal cord of EAE mice. Most
importantly, EAE-induced MMP3 and MMP9 expression
in the spinal cord were strongly suppressed by DMI treat-
ment that might contribute to the alleviation of BBB
disruption in the spinal cord of DMI-treated EAE mice.
Currently, more than ten disease-modifying therapies
are available for relapsing forms of MS. Among them,
interferon beta, a cytokine with immunomodulatory
properties, has been shown to modify disease through
inhibiting Th1 and Th17 differentiation, and promoting
IL-10 production [42–46]. Glatiramer acetate, a random
polymer composed of four amino acids found in myelin
basic protein, was reported to shift T cell population
from Th1 cells to Th2 cells, resulting in the suppression
of the inflammatory response [47, 48]. Natalizumab, a
humanized monoclonal antibody targeting the α4 sub-
unit of VLA4 adhesion molecule on the surface of
lymphocyte, has been shown to prevent the binding be-
tween VLA4 and VCAM-1 on brain vascular endothe-
lium, resulting in suppressed pathogenic T cell
infiltration of the CNS [49]. Dimethyl fumarate (DMF),
an orally administered fumarate ester, was recently ap-
proved by FDA. Although the precise mechanism of ac-
tion of DMF in MS is not completely characterized, it
was reported that DMF is rapidly hydrolyzed to its active
metabolite, monomethyl fumarate (MMF) by esterases,
and MMF exerts neuroprotective effects by activating
Nrf2/HO-1 pathway [50]. In addition, we have previously
shown that DMF attenuated LPS-induced MG activation
and long-term memory deficits through Nrf2-dependent
and independent mechanisms [51]. In this study, we
identified that DMI induced Nrf2/HO-1 pathway in pri-
mary MG and suppressed MG activation in EAE, sug-
gesting that DMI may exert a similar protective
mechanism as DMF.
Although we observed DMI ameliorated disease sever-
ity in EAE, further studies would be required to address
the limitations on the current study. For instance, as we
show that DMI inhibited Th1/Th17 differentiation
in vivo and in vitro, it would be of interest to investigate
whether DMI-induced Nrf2/HO-1 activation has a direct
effect on the suppression of pathogenic Th1/Th17 differ-
entiation. In addition, as we found that DMI suppressed
Fig. 7 DMI alleviates the severity of relapse in relapsing-remitting EAE. SJL/J mice (n = 12/group) were immunized with PLP139–151 to induce EAE.
Following the first remission and before the onset of relapse, EAE mice were administered i.p. with vehicle or DMI (400 mg/kg) every day. The
clinical score of EAE mice was evaluated for a period of 20 days. The incidence and mortality rate of vehicle- and DMI-treated EAE mice were
accessed, and the mean ± SEM of onset of disease, maximum score, average score, and cumulative score of day 1 to day 20 post-treatment in
vehicle- and DMI-treated EAE was calculated. Statistical significance was determined as *p < 0.05, **p < 0.01, and ***p < 0.001 by Mann-Whitney
U test
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MMP3 and MMP9 production that subsequently led to
alleviated BBB disruption in the spinal cord of EAE, it
would be important to elucidate the molecular mecha-
nisms underlying the inhibitory effect of DMI on MMP3
and MMP9 production. Finally, as the CNS resident
cells, including neurons, MG, astrocytes, and brain
endothelial cells, and the CNS infiltrating immune cells
may contribute to the production of MMP3 and MMP9
in the spinal cord of EAE, further studies would be re-
quired to dissect what cell types of MMP3 and MMP9
producers modulated by DMI treatment in EAE.
Conclusions
In this study, we reported for the first time that DMI, an
itaconate derivative, exerted a protective effect in chronic
C57BL/6 EAE. We identified that DMI suppressed LPS-
induced cell activation and inflammatory cytokine produc-
tion in primary MG and ameliorated MG-mediated neu-
roinflammation in EAE. Furthermore, DMI alleviated
EAE-induced BBB disruption, and this protective effect
might be mediated through its inhibitory effect on MMP3
and MMP9 production. Moreover, DMI inhibited periph-
eral Th1/Th17 differentiation and repressed Th1/Th17
infiltration of the CNS in EAE. Finally, DMI exhibited a
therapeutic effect on alleviating the severity of relapse in
relapsing-remitting SJL/J EAE. In conclusion, we demon-
strate that DMI suppresses neuroinflammation and ame-
liorates disease severity in EAE through multiple cellular
and molecular mechanisms, suggesting that DMI can be
developed as a novel therapeutic agent for the treatment
of MS/EAE through its immunomodulatory and anti-
inflammatory properties.
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Additional file 1: Figure S1. C57BL/6 mice were immunized with
MOG35-55 and administered i.p. with vehicle or DMI every day starting
from day 3 post-immunization. The clinical score of EAE mice treated
with (A) vehicle, DMI 300 mg/kg (n=5/group), (B) DMI 500 mg/kg (n=10/
group) or DMI 600 mg/kg (n=10/group) was followed for a period of 30
days. The incidence and mortality rate of vehicle- and DMI-treated EAE
mice were accessed, and the mean ± SEM of onset of disease, maximum
score and cumulative score (day 1 to day 30 post-immunization) in ve-
hicle- and DMI-treated EAE was also calculated. Statistical significance
was determined as: *p<0.05, **p<0.01 and ***p<0.001 by Mann-Whitney U
test. Figure S2. C57BL/6 mice were immunized with MOG35-55 and ad-
ministered i.p. with vehicle or 400 mg/kg DMI (n=8/group) every day
starting from day 3 post-immunization. At day 12 post-immunization, ani-
mals were sacrificed, and the brains and spinal cords were harvested
followed by mononuclear cell isolation. The isolated cells were then sub-
jected to staining with anti-CD4 and anti-CD25 antibodies. After wash,
cells were fixed, permeabilized and stained with anti-Foxp3 antibody
followed by FACS analysis. CD4+ cells (3000-5000 events) were acquired
from each brain and spinal cord sample, and the nuclear expression of
Foxp3 in CD4+CD25+ cells was determined. Isotype controls (ISO) were
used as a negative control to determine CD4+CD25+ cells positive for
the nuclear expression of Foxp3. Data represent mean ± SEM. Statistical
significance was determined as: N.S., no significant difference by unpaired
t test. Figure S3. C57BL/6 mice were immunized with MOG35-55 and ad-
ministered i.p. with vehicle or 400 mg/kg DMI (n=7/group) every day
starting from day 3 post-immunization. At day 10 post-immunization, ani-
mals were sacrificed, and the superficial and deep cervical lymph nodes
were harvested followed by cell isolation. Cells were then subjected to
FACS analysis to determine (A) the intracellular expression of IFNγ and IL-
17 in CD4+ cells or (B) the nuclear expression of Foxp3 in CD4+CD25+
cells. ISO were used as a negative control to determine CD4+ cells posi-
tive for the intracellular expression of IFNγ or IL-17 or CD4+CD25+ cells
positive for the nuclear expression of Foxp3. Data represent mean ± SEM.
Statistical significance was determined as: N.S., no significant difference
by unpaired t test.
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